Enter Note Done
Go to previous page in this tab
Event
  • Scientific Session
  • Bookmark Icon
  • From Innovation to Integration: Implementing NAMs for Human Risk Assessment in Drug Discovery Toxicology
  • Schedule
    Notes
  • Room 304‚ Convention Center
    Set Timezone


Chair: Wendy Hu, Vividion Therapeutics
Co-Chair: Amy Mihalchik, ToxStrategies LLC

Primary Endorser: Drug Discovery Toxicology Specialty Section


Endorser(s): In Vitro and Alternative Methods Specialty Section


Endorser(s): Clinical and Translational Toxicology Specialty Section


In recent years, drug discovery toxicology has undergone a transformative shift as New Approach Methodologies (NAMs) move from innovative exploratory tools to central roles in the integrated human-relevant risk assessment. This evolution focuses on replacing or refining traditional animal testing with human-relevant systems such as microphysiological systems (MPS), organ-on-a-chip, 3D organoids, and advanced in silico and computational tools. With the recent momentum provided by the FDA Modernization Act and the 2025 FDA Roadmap, the pharmaceutical industry is at a pivotal point for adopting non-animal alternatives. This workshop aims to discuss recent progress that has been made in the development, validation, and application of NAMs throughout the drug discovery toxicology processes. The core of NAMs implementation is the “fit-for-purpose” approach, which aligns the choice of model system with the specific context of use. We will focus on NAMs models that are developed to address specific concerns, with customized complexity and tailored endpoints, that can prioritize human biological relevance, technical reliability, and mechanistic understanding, instead of merely replicating animal data. By using an interactive format with real-life examples, we would like to showcase current trends in our industry on how NAMs have been incorporated in an integrated approach for human risk assessment. Despite technical advancement, several hurdles remain for the formal adoption of NAMs in regulatory submissions, including lack of standardization and reproducibility, incomplete representation of systemic crosstalk and longer-term effects, and gaps in bridging to legacy animal-based data. These points will be highlighted in this workshop along with ways that could help augment regulatory acceptance. Expected Outcomes: Participants of this workshop will gain insights into a NAM implementation roadmap, including fit-for-purpose NAMs model development, validation with benchmarks and application in drug discovery toxicology settings. With interactive discussions, they will gain better understanding of strategies for building a weight-of-evidence case using NAMs to support human risk assessment.
Session and Activity Type
Presentations